Immunogenic composition
AssigneeGlaxosmithkline Biologicals SA
InventorsAmirreza Faridmoayer, Rainer Follador, Stefan Jochen Kemmler, Michael Thomas Kowarik, Gerald Johann Posch, Fabio Serventi
Life of this patent
Estimating the term…
Abstract
The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→. Also provided are conjugates comprising a →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.
Claims16
A synthetic pneumococcal saccharide comprising one or more repeat unit(s) →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→;
- wherein the pneumococcal saccharide is conjugated to a carrier protein;
- wherein the carrier protein is selected from a group consisting of CRM1 97, Diphtheria toxoid, tetanus toxoid, detoxified exotoxin A from P. aeruginosa, detoxified hemolysin A of S. aureus, clumping factor A, clumping factor B, E. coli FimH, E. coli FimHC, E. coli heat labile enterotoxin, detoxified variants of E. coli heat labile enterotoxin, Cholera toxin B subunit (CTB), cholera toxin, detoxified variants of cholera toxin, E. coli sat protein, the passenger domain of E. coli sat protein, C. jejuni AcrA, C. jejuni natural glycoproteins, S. pneumoniae pneumolysin, S. pneumoniae NOX, S. pneumoniae PspA, S. pneumoniae PcpA, S. pneumoniae PhtD, S. pneumoniae PhtE, S. pneumoniae ply, and S. pneumoniae LytB;
- wherein the pneumococcal saccharide is a hybrid oligosaccharide or polysaccharide having a structure:
- (B)n-A→ wherein A is an oligosaccharide containing at least 2, 3, 4, 5, 6, 7 or 8 monosaccharides, with a hexose monosaccharide derivative at the reducing end (indicated by the arrow in the diagram):
- wherein B is an oligosaccharide repeat unit →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→;
- and wherein n is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or at least 20.
An immunogenic composition comprising a pneumococcal saccharide comprising one or more repeat unit(s) →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→ conjugated to a carrier protein wherein the carrier protein is selected from a group comprising consisting of detoxified exotoxin A from P. aeruginosa (EPA), TT, DT, CRM197, PhtD, detoxified pneumolysin and protein D;
- wherein the pneumococcal saccharide is a hybrid oligosaccharide or polysaccharide having a structure:
- (B)n-A→ wherein A is an oligosaccharide containing at least 2, 3, 4, 5, 6, 7 or 8 monosaccharides, with a hexose monosaccharide derivative at the reducing end (indicated by the arrow in the diagram):
- wherein B is an oligosaccharide repeat unit →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→;
- and wherein n is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or at least 20.
A pneumococcal saccharide comprising one or more repeat unit(s) →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→ conjugated to a carrier protein, wherein the pneumococcal saccharide is a hybrid oligosaccharide or polysaccharide having a structure:
- (B)n-A→ wherein A is an oligosaccharide containing at least 2, 3, 4, 5, 6, 7 or 8 monosaccharides, with a hexose monosaccharide derivative at the reducing end (indicated by the arrow in the diagram):
- wherein B is an oligosaccharide repeat unit →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→;
- and wherein n is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or at least 20, wherein the carrier protein is attached to a glucose or the hexose monosaccharide derivative of the pneumococcal saccharide.
Dependencies are inferred from the claim text.